CD274 and neoplasm: While biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) have proven effective in predicting responses to immunotherapy, their effectiveness in bone metastases is complicated by the unique immunosuppressive properties of the bone microenvironment [39].